ABSTRACT: Severe myoclonic epilepsy in infants, also known as Dravet syndrome, is a rare refractory form of epilepsy and its control requires a combination of several antiepileptic drugs. We describe a child who had Dravet syndrome unresponsive to a combination of drugs. Work-up for repeated infections revealed immunoglobulin G subclasses deficiency. Administration of intravenous immunoglobulin in addition to valproic acid did not control epilepsy but followed by Vagal Nerve Stimulator, resolution of seizures was sustained.
Introduction:
Conventional antiepileptic drugs did not achieve seizure control in a child with severe myoclonic epilepsy; a combination of valproic acid, intravenous immunoglobulin for immunoglobulin G subclasses deficiency, and Vagal Nerve Stimulator achieved resolution of seizures. This novel combined approach (pharmacological, immunological and surgical) needs further evaluation in a subset of refractory severe myoclonic epilepsy.
Case Presentation:
This 8-year-old girl presented at the age of 4 years with a history of daily seizures since early infancy and recurrent episodes of prolonged febrile status epilepticus for more than 30 minutes necessitating multiple hospital admissions. Her seizures consisted of a combination of daily myoclonic fits, frequent focal, generalized tonic, and generalized tonic-clonic events upon febrile illness often ending up in prolonged status epilepticus. She was the product of a full-term pregnancy and a cesarean delivery with no perinatal complications. She had borderline delayed neurodevelopmental milestones for age upon presentation and a difficult social interaction. Physical exam was unremarkable. Regular blood tests and thyroid functions test were non-revealing. Magnetic resonance imaging of the brain was normal. Multiple EEG recordings had frequent generalized spike waves and polyspike waves as well as multifocal abnormalities. A genetic blood test revealed a novel mutation c.5195C>T/p. Pro 1732Leu of the SCN1 (alpha subunit of the Type I voltage-gated sodium channel) gene that was not present in her parent's blood. Multiple medications were initiated including phenobarbital, valproic acid, topiramate, levetiracetam, lamotrigine, clonazepam, and clobazam, either as monotherapy or in different combinations, to no avail. The drugs did achieve therapeutic blood levels. The parents followed a strict regimen of adherence to medications and medical visits. Unfortunately, stiripentol was not available in our country.
Her neurodevelopmental delay and behavioral problems became more prominent. She was placed in a special school to meet her educational needs.
As she was noted to have very frequent febrile illnesses with accompanying seizures), the immune deficiency was suspected. Work up for immune deficiency revealed low levels of IgG2 (0.822 g/l), IgG3 (0.17g/l) and borderline IgG4 (<0.0691g/l), with the normal reference values being (1.06-6.1g/l), (0.18-1.63g/l) and (0.04-2.30g/l) for each respectively. Total IgG, IgA, and IgM levels were all normal. Upon these findings, the patient was kept only on Valproic acid (40 mg/kg/day) and was given a course of 2g/kg IV IgG (Octagam 10%-Octapharma AG, Lachen, Switzerland) over 5 days repeatedly, every month, for a total course of 6 months. Towards the end of the immunoglobulin course, the seizures were still refractory.
The decision then was to insert a vagal nerve stimulator (VNS-CyberonicsR, Houston, Texas). She underwent a smooth and uneventful surgery and was started on a gradual escalating program till reaching the following parameters: a pulse width of 250 microseconds, a frequency of 20 Hz, a time on for 30 sec, a time off for 5min and an amplitude of 1mA. At that time, more than 50% of seizures had resolved and the febrile events had decreased from monthly to every 4 months.
Currently, the patient is seizure-free for more than 2 years. She is still on Valproic acid and under the same VNS parameters except for a time off for 1.8 min and amplitude of 2 mA. EEG continues to show frequent generalized high voltage and multifocal discharges. Her behavior has improved markedly and she has now better cognitive and scholastic performance with improved social interaction.
Discussion:
Dravet syndrome is a severe form of epilepsy with a great majority having a mutation in SCN1A gene, which encodes a voltage-gated sodium channel Stiripentol was granted an Orphan Designation for the treatment of Dravet syndrome in the US in 2008; however, the drug is still not FDA approved and is not available in a large part of the world, including Lebanon. A systematic review showed only 2 randomized clinical trials evaluating the use of stiripentol (total of 64 children) with findings of the significantly higher proportion of participants having 50% or greater reduction in seizure frequency in the stiripentol group compared with placebo (Inoue et al., 2009). Our patient's seizures were pharmaco-resistant. Thus, a more aggressive intervention was needed to decrease the seizures and secondarily delay progressive cognitive and mental deterioration (Van Rijckevorsel, 2006) .
Concomitant administration of VNS and immunoglobulins in our patient in addition to valproic acid mono pharmacotherapy resulted in resolution of seizures.
As recurrent acute illness seemed to be an important precipitating factor for the development of seizures and status epilepticus in our patient, the evaluation of underlying immunodeficiency was warranted. However 18 Emerging laboratory evidence suggests that VNS, while restraining inflammatory cytokine production in the peripheral nervous system, also exerts a significant CNS neuroprotective function against ischemic stroke injury (Jiang) by inhibiting the apoptosis and oxidant stress responses associated with such injury (Jiang et al., 2015) .
It is unclear which of the above treatment played the major role in decreasing the seizures in our patient or whether there was synergism between the 3 modalities. IV immunoglobulin therapy could have helped to attenuate the seizures severity by the time the effect of the VNS started to work. Whether the beneficial effect of the immuno-modulatory drugs like IV immunoglobulin therapy continues to work, long after its administration course is finished, is unknown. Therefore, IV immunoglobulin could have still helped our patient long after 6 months of the administration. However, it was clear that after the gradual escalation of the VNS parameters the seizures started to decrease markedly.
